A phase Ib study to evaluate repeat doses of MIV 711 in healthy volunteers.

Trial Profile

A phase Ib study to evaluate repeat doses of MIV 711 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2013

At a glance

  • Drugs MIV 711 (Primary)
  • Indications Osteoarthritis; Postmenopausal osteoporosis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Medivir AB
  • Most Recent Events

    • 06 Oct 2013 Results for the 7-day dosing series presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
    • 22 Aug 2013 Data are being analysed and results will be presented at a scientific congress later in 2013, according to a Medivir media release.
    • 05 Jun 2013 Top-line results are expected around mid-year 2013, according to a Medivir media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top